U.S. markets open in 1 hour 6 minutes

CRISPR Therapeutics AG (CRSP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
120.88+6.49 (+5.67%)
At close: 4:00PM EDT

122.79 +1.91 (1.58%)
Pre-Market: 8:22AM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close114.39
Bid0.00 x 1100
Ask0.00 x 1100
Day's Range114.21 - 122.48
52 Week Range46.01 - 220.20
Avg. Volume2,139,327
Market Cap9.118B
Beta (5Y Monthly)2.26
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Is CRSP Stock A Buy or Sell?
    Insider Monkey

    Is CRSP Stock A Buy or Sell?

    While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus spending, many smart money investors are starting to get cautious towards the current bull run since March and hedging or reducing many of their long positions. Some fund managers are betting on Dow hitting […]

  • Motley Fool

    Here's the Holy Grail of Gene Editing

    In this video from Motley Fool Live, recorded on March 15, Fool.com contributors Brian Orelli and Keith Speights discuss the difference between ex vivo gene editing (outside the body) and in vivo editing (within the patient). CRISPR Therapeutics (NASDAQ: CRSP) and its partner Vertex Pharmaceuticals (NASDAQ: VRTX) have mastered ex vivo gene editing, but the strategy is limited to diseases where cells can be manipulated outside the body. Up-and-coming gene editing companies may have a bigger opportunity if they can master the in vivo technique.

  • Crispr Therapeutics Stock Sees Improved Relative Strength Rating
    Investor's Business Daily

    Crispr Therapeutics Stock Sees Improved Relative Strength Rating

    Crispr Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating